F. Tarres-Freixas

VLP-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice

This study develops a neoantigen selection pipeline and a VLP-based vaccine platform to enhance immunogenicity and antitumor activity in mice.

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

A Novel Monoclonal Antibody Targeting a Large Surface of the Receptor Binding Motif Shows Pan-neutralizing SARS-CoV-2 Activity Including BQ.1.1 Variant

This study characterizes a new monoclonal antibody, 17T2, that broadly neutralizes SARS-CoV-2 variants, including BQ.1.1, and shows in vivo prophylactic activity against Omicron BA.1.1.

SARS-CoV-2 B.1.351 (beta) variant shows enhanced infectivity in K18-hACE2 transgenic mice and expanded tropism to wildtype mice compared to B.1 variant

This study shows that the SARS-CoV-2 B.1.351 variant infects K18-hACE2 mice faster and wildtype mice, with milder symptoms than the B.1 variant.

Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals.

The paper assesses how prior SARS-CoV-2 infection affects B.1.1.7 cross-neutralization in vaccinated individuals, finding that previously infected individuals show equivalent neutralization against B.1.1.7 compared to the Wuhan strain.

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

This study tracks neutralizing antibody levels in COVID-19 patients up to six months post-infection, finding persistent activity in mild cases and a slower decline in hospitalized individuals.